Historical Valuation
ADC Therapeutics SA (ADCT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.57 is considered Undervalued compared with the five-year average of -3.28. The fair price of ADC Therapeutics SA (ADCT) is between 5.76 to 7.57 according to relative valuation methord. Compared to the current price of 3.57 USD , ADC Therapeutics SA is Undervalued By 38.07%.
Relative Value
Fair Zone
5.76-7.57
Current Price：3.57
38.07%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
ADC Therapeutics SA (ADCT) has a current Price-to-Book (P/B) ratio of -1.66. Compared to its 3-year average P/B ratio of -1.64 , the current P/B ratio is approximately 1.51% higher. Relative to its 5-year average P/B ratio of 1.55, the current P/B ratio is about -207.12% higher. ADC Therapeutics SA (ADCT) has a Forward Free Cash Flow (FCF) yield of approximately -30.33%. Compared to its 3-year average FCF yield of -71.34%, the current FCF yield is approximately -57.48% lower. Relative to its 5-year average FCF yield of -51.77% , the current FCF yield is about -41.41% lower.
P/B
Median3y
-1.64
Median5y
1.55
FCF Yield
Median3y
-71.34
Median5y
-51.77
Competitors Valuation Multiple
AI Analysis for ADCT
The average P/S ratio for ADCT competitors is 31.11, providing a benchmark for relative valuation. ADC Therapeutics SA Corp (ADCT.N) exhibits a P/S ratio of 5.57, which is -82.08% above the industry average. Given its robust revenue growth of -11.03%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ADCT
1Y
3Y
5Y
Market capitalization of ADCT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ADCT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ADCT currently overvalued or undervalued?
ADC Therapeutics SA (ADCT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.57 is considered Undervalued compared with the five-year average of -3.28. The fair price of ADC Therapeutics SA (ADCT) is between 5.76 to 7.57 according to relative valuation methord. Compared to the current price of 3.57 USD , ADC Therapeutics SA is Undervalued By 38.07% .
What is ADC Therapeutics SA (ADCT) fair value?
ADCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of ADC Therapeutics SA (ADCT) is between 5.76 to 7.57 according to relative valuation methord.
How does ADCT's valuation metrics compare to the industry average?
The average P/S ratio for ADCT's competitors is 31.11, providing a benchmark for relative valuation. ADC Therapeutics SA Corp (ADCT) exhibits a P/S ratio of 5.57, which is -82.08% above the industry average. Given its robust revenue growth of -11.03%, this premium appears unsustainable.
What is the current P/B ratio for ADC Therapeutics SA (ADCT) as of Jan 10 2026?
As of Jan 10 2026, ADC Therapeutics SA (ADCT) has a P/B ratio of -1.66. This indicates that the market values ADCT at -1.66 times its book value.
What is the current FCF Yield for ADC Therapeutics SA (ADCT) as of Jan 10 2026?
As of Jan 10 2026, ADC Therapeutics SA (ADCT) has a FCF Yield of -30.33%. This means that for every dollar of ADC Therapeutics SA’s market capitalization, the company generates -30.33 cents in free cash flow.
What is the current Forward P/E ratio for ADC Therapeutics SA (ADCT) as of Jan 10 2026?
As of Jan 10 2026, ADC Therapeutics SA (ADCT) has a Forward P/E ratio of -3.13. This means the market is willing to pay $-3.13 for every dollar of ADC Therapeutics SA’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for ADC Therapeutics SA (ADCT) as of Jan 10 2026?
As of Jan 10 2026, ADC Therapeutics SA (ADCT) has a Forward P/S ratio of 5.57. This means the market is valuing ADCT at $5.57 for every dollar of expected revenue over the next 12 months.